ANKTIVA

CULVER CITY, Calif., July 29, 2026 ImmunityBio announced that the Emirates Drug Establishment (EDE) has granted Marketing Authorization for...

CULVER CITY, Calif., June 1, 2026 ImmunityBio announced new clinical and comparative data from its ANKTIVA® (nogapendekin alfa inbakicept-pmln)...

CULVER CITY, Calif., May 19, 2026 ImmunityBio announced that the U.S. Food and Drug Administration (FDA) has accepted its...

CULVER CITY, Calif. – May 5, 2026 ImmunityBio Inc. has announced it will present new comparative clinical data and...

MILWAUKEE, Feb. 21, 2026 — New research presented at the 2026 Annual Meeting of the American Academy of Allergy,...

SAN DIEGO & RIYADH — February 20, 2026 — Immunotherapy innovator ImmunityBio has announced a strategic partnership with regional...

Conditional Approval Expands Access to 33 Countries February 18, 2026 | Culver City, California ImmunityBio announced that the European...